Information between 12th March 2024 - 21st April 2024
Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.
Parliamentary Debates |
---|
Disability Benefits
44 speeches (8,647 words) Tuesday 26th March 2024 - Westminster Hall Department for Work and Pensions Mentions: 1: Tanmanjeet Singh Dhesi (Lab - Slough) research found that the current disability assessment system is not fit for purpose for those living with multiple - Link to Speech |
Written Answers |
---|
Health: Technology
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough) Tuesday 26th March 2024 Question to the Department of Health and Social Care: To ask the Secretary of State for Health and Social Care, whether the NHS is taking steps with (a) technology developers and (b) academia to help accelerate the introduction of innovative medical solutions. Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care) In February 2023, the Department published the MedTech strategy which outlined how we will work with key stakeholders, including technology developers and academia, to ensure the health and social care system can reliably access safe, effective, and innovative medical technologies. To accelerate the introduction of innovative medical solutions, we are working with stakeholders at pace to implement solutions to streamline and join-up the innovation adoption pathway, from providing clear signals to industry on the innovation we need, to reforming regulation, comparative assessment, and with clearer procurement pathways.
In October 2023, the Government announced £30 million of investment in the Health Tech Adoption and Acceleration Fund. The fund is supporting integrated care systems to invest in the latest technology to help cut waiting lists, speed up diagnosis, and deliver new and improved ways to treat patients. Thanks to this fund, tens of thousands of patients at risk of kidney disease will be able to get tested from the comfort of their own homes. In February 2024, the Government announced eight innovative tech companies who will be supported to bring their devices to market through the Innovative Devices Access Pathway (IDAP). One of the technologies allows chemotherapy patients to self-test at home, using a finger-prick blood test, for neutropenic sepsis. Another is a smartphone app that delivers exercises, cognitive behaviour therapy, and targeted physical activity in a personally customisable format to help patients manage multiple sclerosis. |
Health: Technology
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough) Tuesday 26th March 2024 Question to the Department of Health and Social Care: To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help encourage innovation in the development of healthcare technology for at home use. Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care) In February 2023, the Department published the MedTech strategy which outlined how we will work with key stakeholders, including technology developers and academia, to ensure the health and social care system can reliably access safe, effective, and innovative medical technologies. To accelerate the introduction of innovative medical solutions, we are working with stakeholders at pace to implement solutions to streamline and join-up the innovation adoption pathway, from providing clear signals to industry on the innovation we need, to reforming regulation, comparative assessment, and with clearer procurement pathways.
In October 2023, the Government announced £30 million of investment in the Health Tech Adoption and Acceleration Fund. The fund is supporting integrated care systems to invest in the latest technology to help cut waiting lists, speed up diagnosis, and deliver new and improved ways to treat patients. Thanks to this fund, tens of thousands of patients at risk of kidney disease will be able to get tested from the comfort of their own homes. In February 2024, the Government announced eight innovative tech companies who will be supported to bring their devices to market through the Innovative Devices Access Pathway (IDAP). One of the technologies allows chemotherapy patients to self-test at home, using a finger-prick blood test, for neutropenic sepsis. Another is a smartphone app that delivers exercises, cognitive behaviour therapy, and targeted physical activity in a personally customisable format to help patients manage multiple sclerosis. |
Department Publications - Transparency |
---|
Friday 12th April 2024
Home Office Source Page: Non-technical summaries granted in 2024 Document: Non-technical summaries: projects granted in 2024, January to March (PDF) Found: For example, Multiple Sclerosis (MS) is a focus of the research in this project. |
Department Publications - Guidance |
---|
Tuesday 9th April 2024
Department for Work and Pensions Source Page: Employing disabled people: Disability Confident and CIPD manager’s guide Document: Recruiting, managing and developing disabled people: a practical guide for managers [print-ready PDF] (PDF) Found: Some conditions are automatically considered disabilities, such as cancer, HIV infection and multiple |
Tuesday 9th April 2024
Department for Work and Pensions Source Page: Employing disabled people: Disability Confident and CIPD manager’s guide Document: Recruiting, managing and developing disabled people: a practical guide for managers [accessible PDF] (PDF) Found: Some conditions are automatically considered disabilities, such as cancer, HIV infection and multiple |
Non-Departmental Publications - News and Communications |
---|
Mar. 14 2024
Employment Appeal Tribunal Source Page: Rentokil Initial UK Ltd v Mr M Miller: [2024] EAT 37 Document: Rentokil Initial UK Ltd v Mr M Miller [2024] EAT 37 (PDF) News and Communications Found: In March 2017 he was diagnosed with multiple sclerosis. |
Non-Departmental Publications - Transparency |
---|
Mar. 14 2024
Medicines and Healthcare products Regulatory Agency Source Page: Freedom of Information responses from the MHRA - week commencing 29 May 2023 Document: FOI 23/351 - attachment 1 (PDF) Transparency Found: Multiple Sclerosis Gene tics Consortium 2007 , International Multiple Sclerosis Genetics Consortium |
Mar. 14 2024
Medicines and Healthcare products Regulatory Agency Source Page: Freedom of Information responses from the MHRA - week commencing 4 December 2023 Document: FOI 23/774 - attachment 1 (PDF) Transparency Found: Sensory distu rbance (336), Sensory loss (291), Neuropathy peripheral (263), Myelitis transverse (86), Multiple |
Mar. 14 2024
Medicines and Healthcare products Regulatory Agency Source Page: Freedom of Information responses from the MHRA - week commencing 4 December 2023 Document: FOI 23/857 - attachment 2 (PDF) Transparency Found: Disturbance in attention 3 0 Migraine headaches Migraine 23 0 Migraine without aura 1 0 Multiple |
Mar. 14 2024
Medicines and Healthcare products Regulatory Agency Source Page: Freedom of Information responses from the MHRA - week commencing 4 December 2023 Document: FOI 23/736 (PDF) Transparency Found: variation to extend the therapeutic indication for Tecfidera to include treatment of relapsing remitting multiple |
Mar. 14 2024
Medicines and Healthcare products Regulatory Agency Source Page: Freedom of Information responses from the MHRA - week commencing 4 December 2023 Document: FOI 23/774 - attachment 2 (PDF) Transparency Found: Sclerosis MSSR Monthly Summary Safety Report NA Neuralgic Amyotrophy NAbs Neutralizing Antibodies |
Mar. 14 2024
Medicines and Healthcare products Regulatory Agency Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023 Document: FOI 23/905 - attachment 3 (PDF) Transparency Found: types 1 and 2 Chronic Neurological diseases Generalised convulsions Dementia Demyelination multiple |
Mar. 14 2024
Medicines and Healthcare products Regulatory Agency Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023 Document: FOI 23/908 - attachment 3 (PDF) Transparency Found: Exertional headache 1 External compression headache 1 Thunderclap headache 1 Tongue paralysis 1 Multiple |
Mar. 14 2024
Medicines and Healthcare products Regulatory Agency Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023 Document: FOI 23/905 - attachment 2 (PDF) Transparency Found: sclerosis No Hemiplegia No Parkinson’s disease No Neuron motor disease No Down's syndrome No |
Mar. 14 2024
Medicines and Healthcare products Regulatory Agency Source Page: Freedom of Information responses from the MHRA - week commencing 18 December 2023 Document: FOI 23/905 - attachment 4 (PDF) Transparency Found: and 2 Yes Chronic Neurological diseases Generalised convulsions No Dementia No Demyelination multiple |
Scottish Government Publications |
---|
Friday 19th April 2024
Healthcare Quality and Improvement Directorate Source Page: Scotland's Genomic Medicine Strategy 2024-2029 Document: Genomics in Scotland: Building our Future (PDF) Found: independent expert review, four projects were funded in 2021 in critical care, diabetes, liver disease and multiple |
Thursday 28th March 2024
Agriculture and Rural Economy Directorate Source Page: National Islands Plan Annual Report 2023 Document: National Islands Plan Annual Report 2023 (PDF) Found: Additionally, the Scottish Ballet runs a specific programme for individuals with multiple sclerosis |